Broadly defined, there are currently three approaches to the management of presbyopia, each with its own advantages and disadvantages. External optical correction with spectacles or contact lenses is ...

Spectacles and contact lenses represent the most widely available and accessible presbyopia correction options and are also (together with topical pharmacotherapy) the least invasive. Spectacles also ...

The MarketWatch News Department was not involved in the creation of this content. The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by ...

Presbyopia is defined as age-related loss of near vision that affects nearly everyone over age 45. The FDA has approved Vizz, an aceclidine ophthalmic solution 1.44%, making it the first and only ...

LNZ100 shows superior efficacy and safety in presbyopia treatment, with a strong probability of FDA approval by August 2025. LNZ100 outperforms competitors Vuity and Qlosi, offering faster and greater ...

VUITY, an FDA-approved eye drop for presbyopia, has significant market potential given the growing aging population. With an estimated 128 million Americans affected by presbyopia, VUITY offers a ...

A market for presbyopia eye drops that can sharpen vision with just one drop is expected to officially open in South Korea. Kwangdong Pharmaceutical announced on the 13th that its presbyopia treatment ...

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene ...

Welcome to the health and wellness podcast. In this episode, we are joined by Irene Gitonga, an optometrist, to discuss the causes, symptoms, and treatment of presbyopia. Tune in to listen.

A Prescription Drug User Fee Act target date of October 17, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...